Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case report describes a 30-year-old woman with keratosis pilaris treated with emollients and keratolytics, resulting in slight improvement.

This study describes a patient with Rothmund–Thomson syndrome-like symptoms who displayed hair improvement after combination therapy, despite carrying an ANAPC1 gene variant of uncertain significance.

This article discusses the causes of hirsutism, identifying increased androgen production and heightened skin sensitivity, and provides no new clinical results.

In this article, the authors discuss Ayurvedic concepts and treatments for Indralupta (Alopecia Areata), highlighting a case successfully managed with Ayurvedic medicine, while contrasting it with modern therapies like corticosteroids and immunosuppressants, which have significant side effects.

This study observed that early treatment with ritlecitinib in patients with alopecia areata, especially when severity is low, led to more favorable responses, and continued improvement was seen up to 24 months, offering guidance on treatment timing and duration.

This study found that tofacitinib and baricitinib had an acceptable adverse reaction profile when used to treat rheumatoid arthritis, with similar side effects to those described in their technical data sheets.

This meta-analysis reports that ritlecitinib significantly improved hair growth in alopecia areata patients compared to placebo, although its potential requires further clinical exploration.

In this study, brepocitinib was found to significantly reduce inflammatory biomarker CCL5 expression and improve clinical severity by week 24, while maintaining a favorable safety profile.

This study retrospectively evaluated the effectiveness of off-label baricitinib in children with severe alopecia areata and found that 50% achieved treatment goals, though psychological effects were noted and laboratory abnormalities occurred in 42.86% of patients.

This study observed that most hirsute patients on combined cyproterone acetate and 'Diane' therapy experienced a reduction in hair growth, with hair becoming softer, thinner, and lighter in color over 12 months.

In this study, a Delphi survey among 441 European dermatology patients identified psychological impacts as the most significant issues affecting their lives, underscoring the need for psychological support in managing dermatological diseases.

In this case report, a 2.5-year-old boy with biotinidase deficiency, initially misdiagnosed due to overlapping symptoms, showed dramatic improvement in several clinical areas after starting biotin supplementation, but persistent sensorineural hearing loss underscored the importance of early diagnosis for preventing irreversible complications.

In this study, ritlecitinib 50 mg produced clinically meaningful improvements in scalp hair regrowth over three years for patients aged 12 and older with severe alopecia areata, with 65.1% showing substantial hair regrowth and 31.2% achieving complete regrowth, while also maintaining a consistent safety profile.

This study found that modeling and simulation effectively informed decision-making and dose selection for ritlecitinib in treating alopecia areata, supporting an accelerated drug development strategy.

This study found that overexpressing PLC5 in Arabidopsis thaliana reduced root growth but improved drought tolerance, and suggests PIP2 is crucial for root hair growth.

This study found that men with early-onset androgenic alopecia may be partially resistant to the cardiometabolic benefits of bromocriptine compared to those with normal hair growth.

This study describes the successful management of Andean bear alopecia syndrome in three female bears using oclacitinib, leading to rapid pruritus resolution and fur regrowth without adverse effects.

In this study, daily application of bimatoprost 0.03% ophthalmic solution for 9 months significantly improved eyebrow appearance in individuals with mild to moderate eyebrow hypotrichosis, without observed side effects.

This study reports the first cases of recessive KRT17-related pachyonychia congenita involving all ectodermal derivatives in seven members of two consanguineous Pakistani families.

In this study, researchers reported that individuals from iodine-deficient regions have an increased risk of developing hypothyroidism from MDR-TB treatment regimens containing PAS and/or Prothionamide.

In this case report, a 17-year-old male with a specific TRPS1 gene mutation presented with sparse, soft hair, short thumbs and toes, misaligned teeth, and distinctive bone abnormalities in the fingers and toes as observed through X-ray analysis.

This study found that in a tertiary academic institution, nearly 1 in 5 dermatology consults were for drug-related skin reactions, with antibiotics frequently identified as the culprits.

Many women in Turkey have hirsutism, according to the research group's findings.

This study found that alopecia in four children was linked to severe calcitriol-resistant rickets, suggesting this condition should be considered among inherited hair growth disorders.

Systematic end-of-trial biopsies are the most reliable way to assess outcomes.

In this case report, a 20-year-old male with tricho-rhino-phalangeal syndrome was found to have a de novo frameshift mutation in the TRPS1 gene, highlighting the challenges in diagnosing this rare disorder.

This study assessed ritlecitinib's effects on sustained hair regrowth in patients with alopecia areata who showed improvement at 24 weeks, confirming ongoing benefits through 48 weeks for scalp, eyebrow, and eyelash hair regrowth in this post hoc analysis.

In this study, ritlecitinib 50-mg showed clinically meaningful efficacy, with improvements in the Severity of Alopecia Tool score observed in patients with alopecia areata over a 3-year period, demonstrating long-term benefit in both clinician- and patient-reported outcomes.

This case study describes a 9-year-old boy with monilethrix and associated abnormalities, suggesting a new, severe autosomal recessive variant termed "monilethrix syndrome.